Edition:
United States

Portola Pharmaceuticals Inc (PTLA.OQ)

PTLA.OQ on NASDAQ Stock Exchange Global Select Market

47.02USD
15 Dec 2017
Change (% chg)

$-0.53 (-1.11%)
Prev Close
$47.55
Open
$47.63
Day's High
$48.09
Day's Low
$46.34
Volume
912,490
Avg. Vol
316,963
52-wk High
$67.10
52-wk Low
$17.74

Select another date:

Tue, Dec 12 2017

BRIEF-Portola Provides Update On European Marketing Authorization Application For Betrixaban

* PORTOLA PHARMACEUTICALS PROVIDES UPDATE ON EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR BETRIXABAN

BRIEF-Portola Pharmaceuticals provides update on Bevyxxa commercial launch

* Portola Pharmaceuticals provides update on Bevyxxa(betrixaban) commercial launch

BRIEF-Portola Pharmaceuticals appoints John Lawrence as chief medical officer

* Portola Pharmaceuticals appoints industry veteran John H. Lawrence, M.D., as senior vice president of product development and chief medical officer Source text for Eikon: Further company coverage:

BRIEF-Portola announces pricing of public offering of common stock at $55 per share

* Portola announces pricing of public offering of common stock

BRIEF-Portola Pharma announces proposed offering of common stock

* Portola Pharmaceuticals announces proposed offering of common stock

BRIEF-Portola Pharmaceuticals ‍says due date for review of BLA for Andexxa is Feb 2, 2018

* Portola Pharmaceuticals announces Andexxa (Andexanet Alfa) Biologics License Application resubmission accepted for review by U.S. FDA

BRIEF-Portola Pharmaceuticals reports Q2 loss per share of $1.22

* Portola Pharmaceuticals reports second quarter 2017 financial results and provides corporate update

BRIEF-Portola announces resubmission of BLA for Andexxa

* Portola Pharmaceuticals announces resubmission of biologics license application for Andexxa (andexanet alfa)

Portola shares soar after FDA approves clot preventing drug

WASHINGTON The U.S. Food and Drug Administration on Friday approved a new oral blood-thinner made by Portola Pharmaceuticals Inc to prevent deep vein thrombosis and pulmonary embolisms in acutely ill patients who are not undergoing surgery.

UPDATE 3-Portola shares soar after FDA approves clot preventing drug

WASHINGTON, June 23 The U.S. Food and Drug Administration on Friday approved a new oral blood-thinner made by Portola Pharmaceuticals Inc to prevent deep vein thrombosis and pulmonary embolisms in acutely ill patients who are not undergoing surgery.

Select another date: